Trial Profile
A efficacy and safety of adalimumab Non-Diabetic moderate-to-severe Psoriatic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 07 Oct 2015 New trial record